Wound Care

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

Jul 10, 2024

POMPANO BEACH, FL, July 10, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, announces that the IRB has approved a clinical study to evaluate AmnioWrap2™ (AW2) in diabetic foot ulcers (DFU), one of the company’s placental-derived allograft commercial products. Jason Matuszewski, CEO of BioStem, commented: “Diabetic foot ulcers are a...

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Jun 26, 2024

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater efficiency in general wound closure POMPANO BEACH, Fla., June 26, 2024 -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that an article validating its proprietary processing method and its placental allograft...

BioStem Technologies to Sponsor MRO Better Half Dash

May 29, 2024

POMPANO BEACH, Fla., May 29, 2024 - BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will sponsor the MRO Better Half Dash which will be held on May 29, 2024, from 4:00 PM – 9:00 PM at the Trackhouse Motorplex, 130 Motorplex Dr, Mooresville, NC. The Better Half Dash has become a beloved annual event in NASCAR, eagerly anticipated by fans and participants alike. Billy...

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

Feb 26, 2024

New York, N.Y. February 26, 2024 - PRISM MarketView announces the release of an insightful interview with BioStem Technologies' (OTC: BSEM) CEO, Jason Matuszewski, discussing the company's strategic focus on revolutionizing the wound care market through innovative regenerative medicine solutions. BioStem Technologies, a frontrunner in regenerative medicine, is dedicated to leveraging the healing properties of placental-derived allografts to enhance wound care. The company stands out for its...

PRISM MediaWire – Weekly Press Resume – Nov. 6 to Nov. 10, 2023

Nov 10, 2023

New York, New York, Nov. 10, 2023 PRISM MediaWire - Weekly Press Resume Nov. 6 to Nov. 10, 2023 Two Hands Corporation Launches Sports Illustrated Line Protein Bars in Canada https://prismmediawire.com/two-hands-corporation-launches-sports-illustrated-line-protein-bars-in-canada/ BioStem Technologies to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023...

NEWSROOM

BioStem Receives Institutional Review Board (IRB) Approval to Advance a Clinical Study Evaluating AmnioWrap2™ in Diabetic Foot Ulcers

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

BioStem Technologies to Sponsor MRO Better Half Dash

PRISM MarketView Spotlights BioStem Technologies in the Expanding Wound Care Market

PRISM MediaWire – Weekly Press Resume – Nov. 6 to Nov. 10, 2023

Contact Us